News headlines about DelMar Pharmaceuticals (NASDAQ:DMPI) have been trending somewhat positive on Friday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DelMar Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0403937500025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) opened at $0.83 on Friday. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). equities analysts forecast that DelMar Pharmaceuticals will post -0.54 EPS for the current fiscal year.
A number of brokerages have recently commented on DMPI. HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th.
In other news, CEO Saiid Zarrabian purchased 60,900 shares of the stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have bought 108,400 shares of company stock valued at $89,713.
TRADEMARK VIOLATION WARNING: This piece was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://ledgergazette.com/2017/12/15/delmar-pharmaceuticals-dmpi-getting-somewhat-positive-news-coverage-analysis-finds.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.